RxDoctor Payments Data

Thuy le

Nephrology · Lumberton, NCNPI 1255869970

Payments from drug & device makers

$1,852in general payments, 2019–2025

Across 80 payments — averaging $23.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$344
  • Novartis$205
  • Aurinia Pharma U.S., Inc.$162
  • Travere Therapeutics, Inc.$143
  • Daiichi Sankyo Inc.$134
  • Mallinckrodt Hospital Products Inc.$125
  • plus $738 from 12 others

What the payments were for

  • Food & beverage$1,76095%
  • Education$935%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,852 in reported general payments places this provider in the 55th percentile of 366 nephrology providers in North Carolina.

See all nephrology providers in North Carolina

Medicare billing

Part B allowed, 2024
$100,509
Medicare patients
196
Services billed
838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin141$94,036
FarxigaDapagliflozin Propanediol82$58,858
KerendiaFinerenone40$28,629
Sevelamer Carbonate18$7,156
Losartan Potassium156$941
Allopurinol45$423
Telmisartan19$379
Atorvastatin Calcium53$360
Chlorthalidone23$287
Furosemide73$260
Lisinopril33$179
Doxazosin Mesylate19$174
Carvedilol26$174
Amlodipine Besylate40$171
Cefdinir11$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$56$94,036141 claims
AstraZenecaFarxiga$68$58,85882 claims
BayerKerendia$344$28,62940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 366 nephrology providers in North Carolina.

Other nephrology in Lumberton

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →